Skip to content

Clinical trials

Pulmonary Disease, Chronic Obstructive trials in Italy with no applicable phase

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Pulmonary Disease, Chronic Obstructive Phase: Not applicable Country / region: Italy Clear all

74 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20011
20041
20051
20072
20083
20093
20102
20113
20122
20133
20143
20153
20165
20172
20183
20195
20203
20215
20224
20236
20247
20253
20264

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed40
Unknown status14
Recruiting13
Not yet recruiting3
Terminated2
Active, not recruiting1
Suspended1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Istituti Clinici Scientifici Maugeri SpA11
Fondazione Don Carlo Gnocchi ETS8
Fondazione Salvatore Maugeri4
IRCCS Azienda Ospedaliero-Universitaria di Bologna4
Università degli Studi di Ferrara4
Fondazione Policlinico Universitario Agostino Gemelli IRCCS2
Maugeri Foundation2
Policlinico Hospital2
Pulmonx Corporation2
Regione Veneto2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Pulmonary Disease, Chronic Obstructive74
Heart Failure7
Emphysema4
Dyspnea3
Hypercapnia3
Lung Neoplasms3
Respiratory Insufficiency3
Bronchiectasis2
Bronchitis, Chronic2
Diabetes Mellitus2

Trials

Showing 1 to 25 of 74. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.